<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901067</url>
  </required_header>
  <id_info>
    <org_study_id>COMIRB 16-0391</org_study_id>
    <nct_id>NCT02901067</nct_id>
  </id_info>
  <brief_title>STAT-STatin and Aspirin in Trauma</brief_title>
  <acronym>STAT</acronym>
  <official_title>STAT (STatins and Aspirin in Trauma) Trial: A Phase II, Pragmatic, Prospective, Randomized, Double-blind, Adaptive Clinical Trial Examining the Efficacy of Statins and Aspirin in the Reduction of Acute Lung Injury and Venous Thromboembolism in Patients With Fibrinolysis Shutdown</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denver Health and Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denver Health and Hospital Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial
      examining the efficacy of statins and aspirin in the reduction of acute lung injury and
      venous thromboembolism in patients with fibrinolysis shutdown.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a Phase II, pragmatic, prospective, randomized, double-blind,
      adaptive clinical trial comparing combination rosuvastatin and aspirin therapy to placebo.
      Currently, there is no treatment for fibrinolysis shutdown or effective measures to prevent
      macro- and micro-thrombosis post-injury, thus, placebos are acceptable as the control group.
      Treatment for both groups would otherwise be by standard of care, which includes
      pharmacologic thromboembolism prophylaxis. The safety of concomitant use of VTE
      pharmacological prophylaxis with statins and aspirin is well documented in cardiac surgery
      patients.

      Eligible adult patients with anticipated ICU admission will be screened for eligibility in
      the STAT trial (see inclusion/exclusion criteria) based on history, physical exam and
      clinical data obtained during their initial treatment. If deemed eligible for enrollment in
      the STAT trial, the patient, their legally authorized representative (LAR), or their proxy
      decision-maker will be contacted by our on-site professional research assistants (PRAs) for
      consent to enroll in the study. Only patients for whom consent is obtained within 24 hours
      post-injury will be eligible for randomization into the treatment phase of the study.

      Upon consent, blood samples will be obtained immediately after consent at 6, 12, 24, 48, 72,
      120 and 168 hours after injury. Traditional and tPA-Challenge TEG will be performed on these
      samples to evaluate the development of the three fibrinolysis phenotypes. Upon receiving an
      order for prophylactic anticoagulation, the DHMC pharmacy will randomize the patient to the
      control or intervention arms of the study. Randomization will occur using a
      computer-generated block (groups of 20 patients) random number sequence in sealed, opaque
      envelopes maintained at the DHMC pharmacy. Patients assigned to the intervention arm will
      receive the standard of care anticoagulation plus the combination experimental drugs (20mg of
      rosuvastatin daily and 325mg of aspirin) daily either orally or crushed via feeding tube.
      These doses are consistent with those currently recommended in the postoperative period
      following cardiac surgery. Patients assigned to the control group will receive
      identical-looking placebos at the same time points as the experimental group either orally or
      crushed via feeding tube.

      Healthcare providers, PRAs and patients will be blinded to study allocation standard of care
      anticoagulation plus the combination placebos (produced to look and group assignment (double
      blind design).

      The DHMC pharmacist will be aware of the patient's treatment arm so that rapid un-blinding
      will be possible in the event of an adverse event possibly related to a study medication. The
      blood samples will be used to monitor for type of fibrinolysis, function of the biochemical
      mediators of coagulation and potential side effects of these medications, as explained in
      more detail below.

      Study medications or placebo will be administered during ICU admission while patients are
      receiving the standard of care dosing of prophylactic anticoagulation (i.e. heparin or
      heparin-derivatives) and will be interrupted concomitantly with interruption of
      pharmacological VTE prophylaxis. Patients diagnosed with VTE will be withdrawn from the study
      drugs and will receive the appropriate VTE treatment per current ICU protocols.

      The investigators will monitor function/damage of liver, renal and muscle before initiation
      of therapy (if the patient already has a recent test of these functions up to 12 hours prior
      to the initiation of therapy, the result of this test will be used to avoid unnecessary
      sampling), and upon the end of the therapy or as clinically necessary (i.e., any clinical
      indications of organ dysfunction). Stopping rules are:

        1. Bleeding: Any ongoing bleeding requiring blood transfusion or operative procedure.
           Bleeding will be monitored via monitoring of the daily measurements of hemoglobin
           levels, which are an integral part of the ICU protocols for trauma patients. Study
           medications will be unblinded and stopped if there is a drop in hemoglobin level greater
           than 2 g/dl within 24 hours after the start of study medication, or a drop in hemoglobin
           level greater than 1 g/dl daily for three consecutive days following the start of
           treatment, or requirement of &gt;=1 unit of red blood cells or an operative procedure to
           stop bleeding after the start of study medication;

        2. Liver dysfunction: Alteration in liver chemistry is a rare sequela of statin therapy. A
           meta-analysis of 13 placebo-controlled trials incorporating nearly 50,000 patients
           examined the incidence of liver toxicity (defined as elevation of hepatic transaminases
           greater than 3 times the upper limit of normal) in patients receiving statin therapy. 77
           This study reported the incidence of elevated AST or ALT in statin-treated patients vs
           placebo controls as 1.14% and 1.05%, respectively (OR 1.25; 95% CI 0.99-1.62). Further,
           the only individual drug associated with a statistically significant elevation in
           transaminases over a follow-up interval exceeding 3 years was fluvastatin. These and
           more recent data have informed expert opinion, 78 which ultimately prompted the FDA in
           2012 to revoke the recommendation that liver function tests be monitored in patients
           taking statins. That said, given our at-risk patient population, the investigators will
           use the accepted definition of 3 times the upper limit of normal as the criterion for
           interruption of therapy;

        3. Renal dysfunction: While transient proteinuria has been observed in patients undergoing
           statin therapy, acute kidney injury (AKI) is a rare complication. The JUPITER randomized
           controlled trial incorporating approximately 17,000 patients and comparing rosuvastatin
           to placebo found no difference in AKI (6.0% v 5.4%; p = 0.08) between the groups. 79 In
           a randomized trial comparing rosuvastatin to atorvastatin, simvastatin and pravastatin,
           acute renal failure was observed in 2 of 420 patients receiving high-dose rosuvastatin.
           80 The investigators will define AKI as serum creatinine increase greater than 2x of
           baseline (&gt;Grade 1, based on AKIN criteria) as the criterion to interrupt therapy.

        4. Muscle injury: Myositis and rhabdomyolysis are rare sequela of statin therapy. A
           meta-analysis of 26 studies incorporating nearly 130,000 patients identified an
           incidence of between 1 and 4 per 10,000 patients developing rhabdomyolysis following
           statin therapy. 81 This meta-analysis includes a study of 12,000 patients comparing the
           efficacy of simvastatin 80mg with 20mg doses. In this study, the overall incidence of
           myolysis and rhabdomyolysis were 0.5 and 0.1 per 1000 person-years, respectively,
           wherein all cases of rhabdomyolysis occurred in the high dose cohort. The accepted
           definition of myositis is muscle pain in the setting of a serum creatinine kinase
           concentration greater than 10 times the upper limit of normal. will use this threshold
           to clinically quantify myositis, preceding potential development of rhabdomyolysis, as
           well as the criterion to interrupt therapy.

      Any of the above mentioned stopping rules will be reported as a SAE and will trigger an
      immediate review by the DSMB.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of VTE</measure>
    <time_frame>Day 5 or ICU discharge or upon symptoms of VTE (whichever comes first)</time_frame>
    <description>Based on screening duplex ultrasound (US) of legs and central line on day 5 or upon ICU discharge or upon symptoms of VTE (whichever comes first).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrinolysis phenotypes</measure>
    <time_frame>During ICU stay at the following timepoints - 6, 12, 24, 48, 72, 120 and 168 hours</time_frame>
    <description>Measured by traditional and tissue plasminogen activator (tPA) - Challenge thrombelastography (TEG) lysis at 30 minutes (LY30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen activator inhibitor (PAI) - 1 and tissue plasminogen activator (tPA) levels in plasma</measure>
    <time_frame>During ICU stay at the following timepoints - 6, 12, 24, 48, 72, 120 and 168 hours</time_frame>
    <description>To be measured in platelet poor plasma (PPP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute lung injury (ALI)</measure>
    <time_frame>Within two weeks post-injury</time_frame>
    <description>Based on Berlin Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator days</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>As measured by ventilator-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of arterial thrombotic complications: myocardial infarction (MI) and cerebrovascular accident (CVA).</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) days</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>As measured by ICU-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of multiple organ failure (MOF)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>As measured by Denver MOF score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Wounds and Injuries</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin and Rosuvastatin</intervention_name>
    <description>Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Aspirin and Rosuvastatin)</intervention_name>
    <description>Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Hospital trauma activation

        Exclusion criteria for prophylactic anticoagulation and for the study are:

          -  Known inherited bleeding disorder or coagulopathy

          -  Known contraindication to pharmacologic anticoagulation

          -  Spinal column fracture with epidural hematoma

          -  Head trauma/central nervous system injury

          -  Severe TBI; defined as abbreviated injury score (AIS) Head â‰¥ 3

          -  Intracranial hemorrhage; subdural or epidural hematoma

          -  Spine injury with cord injury symptoms

          -  Neurosurgery service objection; neurosurgical contra-indications will be documented

          -  Ongoing hemorrhage requiring blood product transfusion

          -  Placement of an epidural pain catheter

          -  Thrombocytopenia (platelet count &lt; 50,000)

          -  Non-operatively managed liver or spleen injuries Grade III or above

          -  Known chronic kidney disease (GFR &lt; 15ml/min)

          -  Rising creatinine (Cr &gt; 1.5x baseline) at the time of screening

          -  Inclusion in any other clinical trial

          -  Receiving statin or aspirin therapy pre-injury, as potentially being assigned for
             Control would increase patient's risks

          -  Known allergy to statins or aspirin

          -  Pregnant patients

          -  Prisoners, as their ability to freely consent is impaired

          -  Inability to obtain consent from patient or proxy prior to 24 hours post-injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest E Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arsen Ghasabyan, MPH</last_name>
    <phone>3036023795</phone>
    <email>arsen.ghasabyan@dhha.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Chandler</last_name>
    <email>james.chandler@dhha.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ernest E. Moore, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Denver Health and Hospital Authority</investigator_affiliation>
    <investigator_full_name>Ernest Moore</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

